Tag: edoxaban
Study reports low rates of bleeding and VTE after 12 months...
Daiichi Sankyo Europe GmbH has announced results from five analyses of 12-month data from ETNA-VTE (Edoxaban treatment in routine clinical practice in patients with...
Edoxaban emerges as alternative to dalteparin for cancer-associated VTE
A new analysis has identified patient populations with cancer-associated venous thromboembolism (VTE) who could benefit from treatment with oral anticoagulant edoxaban, taken once daily.
Daiichi...
First patient enrolled in Daiichi Sankyo European edoxaban registry
The first patient has been enrolled in Daiichi Sankyo’s EMIT-AF/VTE (Edoxaban Management in Diagnostic and Therapeutic Procedures) study. This registry will collect real-world clinical...